Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Kioa Lente Wijnsma, Rob ter Heine, Dirk Jan A.R. Moes, Saskia Langemeijer, Saskia E.M. Schols, Elena B. Volokhina, Lambertus P. van den Heuvel, Jack F.M. Wetzels, Nicole C.A.J. van de Kar, Roger J. Brüggemann

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

78 Citaten (Scopus)

Samenvatting

Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.

Originele taal-2Engels
Pagina's (van-tot)859-874
Aantal pagina's16
TijdschriftClinical Pharmacokinetics
Volume58
Nummer van het tijdschrift7
DOI's
StatusGepubliceerd - 1 jul. 2019
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab'. Samen vormen ze een unieke vingerafdruk.

Citeer dit